03rd week of 2009 patent applcation highlights part 48 |
Patent application number | Title | Published |
20090018142 | Use of phosphatases to treat tumors overexpressing N-CoR - This invention provides a method of treating a patient suffering from a tumor overexpressing N—CoR comprising administering to the patient a phosphatase ligand, alone or in combination with a retinoid receptor ligand, a histone deacetylase ligand, or both, in amounts effective to treat the patient. This invention also provides a method of inhibiting tumor growth in a patient suffering from a tumor overexpressing N—CoR. This invention further provides a method of identifying a compound or a mixture of compounds capable of inducing differentiation of cells of a tumor overexpressing N—CoR. This invention still further provides a method of determining the likelihood of successfully treating a subject suffering from a tumor overexpressing N—CoR. This invention also provides a method of assessing the likelihood that a patient is suffering from a tumor overexpressing N—CoR. This invention yet also provides a method of assessing the likelihood that a patient previously suffering from and treated for a tumor overexpressing N—CoR has suffered a recurrence of a tumor overexpressing N—CoR. Finally, this invention provides analogous methods for use on glioblastoma multiforme. | 2009-01-15 |
20090018143 | Thio-substituted arylmethanesulfinyl derivatives - The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): | 2009-01-15 |
20090018144 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS - The present invention relates to compounds represented by formula (I): | 2009-01-15 |
20090018145 | Compositions and their use as anti-tumor agents - The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreating carcinomas) and mesotheliomas. | 2009-01-15 |
20090018146 | Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors - The present invention provides therapeutic compositions comprising a natural triterpenoid and a proteasome inhibitor. These compositions will be particularly useful in the treatment of malignancies and inflammation. The present invention also provides methods of treating a subject having a malignancy or an inflammatory disorder comprising administering to the subject a natural triterpenoid and a proteasome inhibitor. | 2009-01-15 |
20090018147 | Compounds for modulating TRPV3 function - The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. | 2009-01-15 |
20090018148 | Xanthine Derivatives, Processes For Preparing Them And Their Uses - The present invention concerns xanthine derivatives, having formula (I), processes for preparing them, pharmaccutical compositions containing them and their use as pharmaceuticals. | 2009-01-15 |
20090018149 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections - Described are 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of mycobacteria-induced infections and opportunistic infections, as well as compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene derivative and/or pharmaceutically acceptable salts thereof. Furthermore, the present application refers to the use of mycobacterial protein serine/threonine kinases for developing methods for detection and determination of these kinases for recognising and monitoring diseases and for controlling therapy of diseases. | 2009-01-15 |
20090018150 | 5-Ht2b Receptor Antagonists - Compounds of formulae: (I), (II), (IIIa), (IIIb), (IVa) and (IVb): or a pharmaceutically acceptable salt thereof, for use as pharmaceuticals, in particular for the treatment of a condition alleviated by antagonism of a 5-HT | 2009-01-15 |
20090018151 | Topical Treatment of Peripheral diabetic complications - This invention relates to agents for treating, ameliorating, or preventing diabetic complications specifically diabetic neuropathy and skin ulceration by topical application of materials containing one or more arterial or venous dilation components and one or more fast sodium channel inhibitors. Particularly, the invention relates to treating or ameliorating agents that contain minoxidil and its related congeners, which have both potassium channel agonist properties and nitric oxide agonist properties as an active ingredient and which are effective against diabetic complications such as neuropathy, peripheral circulation disorders and skin ulcerations. Unique methods of delivery including delivery through impregnated socks or gloves to match the distribution of pain are also noted. | 2009-01-15 |
20090018152 | Aminophenyl Derivatives as Novel Inhibitors of Histone Deacetylase - This invention comprises the novel compounds of formula (I) | 2009-01-15 |
20090018153 | Substituted Indolyl-Alkyl-Amino-Derivatives as Inhibitors of Histone Deacetylase - This invention comprises the novel compounds of formula (I) wherein R | 2009-01-15 |
20090018155 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 2009-01-15 |
20090018156 | Pyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors - The present invention provides pyrrolo pyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents. | 2009-01-15 |
20090018157 | Chemical compounds - Compounds of Formula (I) wherein: R | 2009-01-15 |
20090018158 | CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE - The invention relates to the essentially pure Λ/-[({2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1 -yl)phenyl]ethyl}amino)carbonyl]-4-methylbenzenesulfonamide Polymorph Forms A and B and to processes for the preparation of, compositions containing and to the uses of, such crystal forms. | 2009-01-15 |
20090018159 | Treatment of Diabetes - The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of diabetic patients. | 2009-01-15 |
20090018160 | Heterocyclic Compounds with Affinity to Muscarinic Receptors - The present invention relates to heterocyclic compounds of the formula (I) | 2009-01-15 |
20090018161 | METHOD FOR PROMOTING GASTROINTESTINAL FUNCTION AND METHOD FOR SCREENING FOR PROMOTER OF GASTROINTESTINAL FUNCTION - The present invention provides a more effective gastrointestinal function promoter. The present invention also provides a method for the prophylaxis or improvement of functional gastrointestinal disorders, a method for appetite regulation and the like. The present invention also provides a method for screening for a substance capable of promoting a gastrointestinal function. The present invention provides a gastrointestinal function promoter containing a T1R agonist as an active ingredient and a method for the prophylaxis or improvement of functional gastrointestinal disorders, a method for appetite regulation and the like by administering a T1R agonist. The present invention also provides a method of screening for a substance capable of promoting a gastrointestinal function which method uses a cell expressing T1R receptor. | 2009-01-15 |
20090018162 | USE OF 6-(3-CHLORO-2-FLUOROBENZYL)-1-[(2S)-1-HYDROXY-3-METHYLBUTAN-2-YL]-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID OR SALT THEREOF FOR TREATING RETROVIRUS INFECTION - The present invention provides a use of a therapeutically effective amount of 6-(3-chloro-2-fluorobenzyl)- | 2009-01-15 |
20090018163 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders - The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders. | 2009-01-15 |
20090018164 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER - The present invention relates to the use of farnesyl protein transferase inhibitors for preparing pharmaceutical compositions for treating advanced breast cancer. | 2009-01-15 |
20090018165 | Biphenyl compounds useful as muscarinic receptor antagonists - This invention provides compounds of formula I: | 2009-01-15 |
20090018166 | New Pyridine Analogues X 161 - The present invention relates to certain new pyridin analogues of Formula (I) | 2009-01-15 |
20090018167 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states - The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiogenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis. | 2009-01-15 |
20090018168 | THERAPEUTIC SUBSTITUTED CHLOROCYCLOPENTANOLS - Disclosed herein is a compound having a formula | 2009-01-15 |
20090018169 | Sulfonamide Derivatives for the Treatment of Bacterial Infections - This present invention is related to sulfonamide derivatives of Formula (I), pharmaceutical composition thereof, methods of preparation thereof and to their use for the treatment and/or prophylaxis of bacterial infections such as tuberculosis. | 2009-01-15 |
20090018170 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases. | 2009-01-15 |
20090018171 | IMIDAZOLE DERIVATIVES - The present invention relates to imidazole derivatives of formula I | 2009-01-15 |
20090018172 | DIPHENYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS OR BKCa CHANNEL MODULATORS - The present invention relates to novel diphenylurea derivatives useful as chloride channel blockers or BK | 2009-01-15 |
20090018173 | Method for controlling the yeast-to-filamentous growth transition in fungi - A method for controlling yeast-to-filamentous growth transition in fungi comprising contacting a fungal cell with an anti-fungal small molecule in an amount effective to reduce or inhibit the yeast-to-filamentous growth transition, wherein the anti-fungal small molecule is 5-(p-Bromobenzylidine)-α-isopropyl-4-oxo-2-thioxo-3-thiozolidineacetic acid or an analog thereof. A method for treating fungal infections comprising contacting one or more fungal cells with an anti-fungal small molecule in an amount effective to control the fungal infection, wherein the anti-fungal small molecule is 5-(p-Bromobenzylidine)-α-isopropyl-4-oxo-2-thioxo-3-thiozolidineactic acid or an analog thereof. | 2009-01-15 |
20090018174 | MACROLIDES AS ANTI-INFLAMMATORY AGENTS - Provided herein are macrolide derivatives that can be useful in treating or preventing inflammatory diseases. Also provided are pharmaceutical compositions comprising one or more macrolide derivatives optionally together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixtures thereof, as well as methods for treating or preventing inflammatory diseases. | 2009-01-15 |
20090018175 | Pharmaceutical excipient complex - The present invention encompasses pharmaceutical excipient complexes comprising combining at least one carrier with an oily substance, and processes for preparing the same, stable pharmaceutical compositions comprising such complexes and active pharmaceutical ingredients and processes for preparing the same. | 2009-01-15 |
20090018176 | FUNGICIDE COMPOSITION COMPRISING AN ARYLAMIDINE DERIVATIVE AND TWO KNOWN FUNGICIDE COMPOUNDS - The present invention relates to a fungicide composition comprising a N | 2009-01-15 |
20090018177 | Propane-1,3-Dione Derivative or Salt Thereof - Compounds useful as GnRH receptor antagonists are provided. The present inventors have further examined propane-1,3-dione derivatives and confirmed as a result that a propane-1,3-dione having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene), or a compound which has benzene or thiophene ring substituted with a group derived from 1-hydroxymethyl, shows excellent availability, in addition to its excellent GnRH receptor antagonism, thereby accomplishing the invention. Since the compound of the invention shows excellent availability, in addition to its strong GnRH receptor antagonism, it can be expected that it exerts superior drug effect in the living body, and it is useful for the treatment of sex hormone dependent diseases such as prostate cancer, breast cancer, endometriosis, uterine leiomyoma, benign prostatic hypertrophy and the like. In addition, since the compound of the invention is excellent in metabolic stability in human and also is less in drug interaction, it has more desirable properties as a medicament to be used for the aforementioned diseases. | 2009-01-15 |
20090018178 | USE OF HALOARYLPYRAZOLE COMPOUNDS IN THE CONTROL OF PARASITE INFESTATION ON ANIMALS - The present invention relates to the use of haloarylpyrazoles as tick-repellent compositions, and to an administration regimen of specific haloarylpyrazoles for controlling ticks on animals. | 2009-01-15 |
20090018179 | NOVEL CRYSTALS AND PROCESS OF MAKING 5-(-METHYL)-2-METHOXY-BENZOIC ACID - The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid. | 2009-01-15 |
20090018180 | 2-IMIDAZOLINES - The present invention relates to compounds of formula I | 2009-01-15 |
20090018181 | DRUG COMPOSITION FOR PREVENTION OR INHIBITION OF ADVANCE OF DIABETIC COMPLICATION - The present invention provides pharmaceutical compositions which can achieve good state of glycemic control and correct postprandial hyperglycemia and early morning fasting hyperglycemia. The present pharmaceutical composition is for administration before meal to prevent or inhibit the progression of diabetic complication, which comprises 5 to 45 mg, as a single dose, of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof (for example, mitiglinide calcium salt hydrate). And said compositions are extremely useful for prevention or inhibition of progression of, for example, diabetic microvascular complications and arteriosclerotic diseases, because the frequency of adverse drug reactions such as hypoglycemic symptoms and gastrointestinal disorders is low. | 2009-01-15 |
20090018182 | Crystalline forms of atorvastatin - Novel forms of atorvastatin hemi-calcium have been prepared and characterized. These novel forms are particularly useful in pharmaceutical compositions. | 2009-01-15 |
20090018183 | N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands - The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: | 2009-01-15 |
20090018184 | Polyether Brevetoxin Derivatives as a Treatment for Cystic Fibrosis, Mucociliary Dysfunction, and Pulmonary Diseases - Disclosed are compounds that are derivatives of brevetoxin, or PbTx, pharmaceutical formulations comprising the compounds, and methods of regulating mucus transport in a cell, treating mucociliary dysfunction and diseases related to decreased mucus transport, wherein the compounds are of the Formula (I), and Formula (III): | 2009-01-15 |
20090018185 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 2009-01-15 |
20090018186 | STABLE BEVERAGE PRODUCTS COMPRISING POLYUNSATURATED FATTY ACID EMULSIONS - A beverage product comprising at least one beverage base and at least one polyunsaturated fatty acid emulsion, said emulsion comprising a continuous liquid phase; an emulsifier; and a discontinuous liquid phase comprising a blend including a polyunsaturated fatty acid source and a dispersing agent, the polyunsaturated fatty acid source comprising at least one polyunsaturated fatty acid, wherein the weight ratio of the fatty acid source to the dispersing agent in the blend ranges from about 9:1 to about 1:10. | 2009-01-15 |
20090018187 | Strontium (M) ascorbate, compositions containing same, method for making same and method of using same - A compound of formula (ascorbate) | 2009-01-15 |
20090018188 | BACTERICIDAL SILVER SURFACTANT DELIVERY INTO COATING AND POLYMER COMPOSITIONS - Disclosed are surfactant compounds and compositions that are antimicrobial. Also provided are polymeric compositions incorporating the surfactant compounds. The polymeric compositions may be used to form antibacterial coatings on surfaces. | 2009-01-15 |
20090018189 | Hormone Sensitive Lipase Modulators And Methods Of Use - Disclosed herein are compound useful for inhibition of hormone sensitive lipase, pharmaceutical compositions of these compounds, and methods of treatment using these compounds. | 2009-01-15 |
20090018190 | Compositions and Methods for Transdermal Oxybutynin Therapy - The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel. | 2009-01-15 |
20090018191 | Deuterated Catecholamine Derivatives and Medicaments Comprising Said Compounds - The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders. | 2009-01-15 |
20090018192 | Methods for Repelling Arthropods Using Isolongifolenone Analogs - A method for for repelling arthropods involving treating an object or area with an arthropod repelling effective amount of at least one isolongifolenone analog (and optionally a carrier or carrier material). | 2009-01-15 |
20090018193 | ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS - The invention concerns the use of essential fatty acids with a high content in eicosapentaenoic acid ethyl ester (EPA) or docosahexaenoic acid ethyl ester (DHA) or a high concentration mixture thereof in the preparation of a medicament useful for preventing mortality, in particular due to sudden death, in patients who have suffered from a myocardial infarction. | 2009-01-15 |
20090018194 | Use of antimicrobial agents derived from alliaceous plants for the prevention and control of crop diseases, post-harvest rot and as environmental disinifectant products - The present invention is directed to utilization of antimicrobial agents derived from plants of the alliaceae family for the prevention and control of crop diseases, post-harvest rotting and as environmental disinfection products. The agents include propyl propylthiosulfinate and propyl propylthiosulfonate compounds for pre- and post-harvest treatments, control of rotting in fruits and vegetables; disinfection of agricultural soils, control of microorganisms, environmental disinfection in agricultural processing industries, facilities and equipment, disinfection of food containers and boxes. The agents can be used as pure active principles or in mixtures, in aqueous solutions or in any formulation, either liquid or supported in a solid agent or formulation; as single active principles or in formulation, together with other synthetic or natural antifungal agents, biocontrol agents, fertilizers, antioxidants, growth regulators or regulators of any other type; by means of immersion, fogging, wetting, spraying, atomization, injection in the soil, in irrigation systems, by means of drenchers or in general any other treatment or application system. | 2009-01-15 |
20090018195 | MICROFLUIDIC CHEMOSTAT - A chemostat is described that includes a growth chamber having a plurality of compartments. Each of the compartments may be fluidly isolated from the rest of the growth chamber by one or more actuatable valves. The chemostat may also include a nutrient supply-line to supply growth medium to the growth chamber, and an output port to remove fluids from the growth chamber. Also, a method of preventing biofilm formation in a growth chamber of a chemostat is described. The method may include the steps of adding a lysis agent to a isolated portion of the growth chamber, and reuniting the isolated portion with the rest of the growth chamber. | 2009-01-15 |
20090018196 | FOOD COMPOSITION COMPRISING AMINO ACIDS - The invention relates to a food composition comprising an amino acid part having at least the amino acids leucine, isoleucine, valine, threonine and lysine in an amount of from about 35 to 90 g/100 g of the total amount of the amino acid part as a method how to produce said food composition. The invention relates to different food products comprising said food composition. | 2009-01-15 |
20090018197 | METHODS FOR TREATING STATUS EPILEPTICUS AND RELATED CONDITIONS - The present invention is directed to the novel use of a class of peptide compounds for treating status epilepticus or related conditions, e.g. acute repetitive seizures, seizure clusters, etc. | 2009-01-15 |
20090018198 | METHOD FOR TREATING A MOTONEURON DISORDER - The present invention is directed to the use of a class of peptide compounds for treating amyotrophic lateral sclerosis (ALS) and other forms of motoneuron diseases and peripheral neuropathies. | 2009-01-15 |
20090018199 | Methods of Administering 3, 3, 14, 14 Tetramethyl Hexadecane 1, 16 Dioic Acid - The present invention provides methods for lowering LDL, VLDL, total cholesterol, triglycerides, Insulin resistance and hypertension, and methods for elevating HDL in subjects in need thereof. Additionally, the present invention provides methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid for the above indications. | 2009-01-15 |
20090018200 | COMPOSITION CONTAINING A PHENANTHRENOL - Novel uses of phenanthrenol compounds for improving the appearance and/or texture of the skin. | 2009-01-15 |
20090018201 | Method of Combating Bugs - A method of combating bugs comprising contacting the bugs or their food supply, habitat, breeding grounds or their locus with a pesticidally effective amount of a compound of the formula (I) wherein W is Cl or CF | 2009-01-15 |
20090018202 | Modafinil compositions - Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy. | 2009-01-15 |
20090018203 | MODIFIED RELEASE COMPOSITIONS OF MILNACIPRAN - A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a T | 2009-01-15 |
20090018204 | COMPOSITION AND METHOD FOR ENHANCING HAIR GROWTH - A composition including a molecule of the formula: | 2009-01-15 |
20090018205 | METHODS FOR TREATMENT OF MIGRAINE AND SYMPTOMS THEREOF - Compositions, methods and kits are provided for the treatment of migraines. The compositions, methods and kits include an effective dose of trimethobenzamide and an ethanolamine antihistamine that, when administered to an individual suffering from migraine headaches, will alleviate symptoms associated with the migraine headaches. Compositions, methods, and kits for the treatment of migraines include pharmaceutical compositions of trimethobenzamide and diphenhydramine. | 2009-01-15 |
20090018206 | PREVENTION OF HYPOTENSION AND STABILIZATION OF BLOOD PRESSURE IN HEMODIALYSIS PATIENTS - The present invention relates to the use of S-alkylisothiouronium derivatives, including S-ethylisothiouronium diethylphosphate, for stabilizing blood pressure in hemodialysis patients. The compositions of the invention are effective in preventing hypotension in hemodialysis patients. | 2009-01-15 |
20090018207 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described. | 2009-01-15 |
20090018208 | Novel Succinate Salt of O-Desmethyl-Venlafaxine - A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided. | 2009-01-15 |
20090018209 | CURCUMIN AND CURCUMINOID INHIBITION OF ANGIOGENESIS - Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It has further been discovered that curcumin acts to inhibit angiogenesis in part by inhibition of basic fibroblast growth factor (bFGF), and thereby provides a means for treating other disorders characterized by elevated levels of bFGF, such as bladder cancer, using curcumin and other analogues which also inhibit bFGF. Representative skin disorders to be treated include the malignant diseases angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Karposi's sarcoma, and the non-malignant diseases or conditions including psoriasis, lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis. | 2009-01-15 |
20090018210 | A Method for Promoting Fat Degradation - A novel, new, and highly effective agent for promoting fat degradation that contains astaxanthin and/or an ester thereof as active ingredient is provided. The agent for promoting fat degradation of the present invention has an effect of reducing fat by lipolysis of fat in either a subject who is in a condition in which fat has already accumulated or a subject who is in a condition in which fat has not yet been accumulated. Accordingly, the agent for promoting fat degradation of the present invention can restore hypertrophied adipocytes to a normal size. | 2009-01-15 |
20090018211 | Method for inhibiting of COX2 and inflammation with phenolic aldehydes - A method for inhibiting of COX2 and inflammation by administering a hydroxybenzaldehyde. | 2009-01-15 |
20090018212 | METHODS OF RELIEVING STRESS - Methods, combinations and compositions for relieving or preventing the effects of stress are provided. In particular, combinations and compositions comprising cis-3-hexen-1-ol, trans-2-hexenal and α-pinene, articles of manufacture impregnated with the combination or composition and methods of relieving stress by exposure to the combination or composition are described. | 2009-01-15 |
20090018213 | ANTIVIRAL METHOD - This invention provides a method of inactivating human noroviruses and other acid stable viruses. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from cationic oligomers and polymers, chaotropic agents, and mixtures thereof. | 2009-01-15 |
20090018214 | Composition for Promoting Vascular Smooth Muscle Relaxation - A composition for topical application to a part of the body comprises a local anaesthetic and optionally a vasodilator as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the active ingredient. The vasodilator may comprise glyceryl trinitrate and the local anaesthetic may comprises an anaesthetic of the aminoamide or aminoester type. The volatile solvent may comprise a mixture of water with a C | 2009-01-15 |
20090018215 | Fumigant for wood parasitic nematodes and wood fumigation method - The present invention provides a fumigant for wood parasitic nematodes comprising methyl iodide dissolved in liquefied carbon dioxide, in place of methyl bromide the use of which is globally regulated as ozone depleting substance or a fumigant using methyl iodide dissolved in liquefied carbon dioxide in combination with one or more compounds selected from the group consisting of sulfuryl fluoride, methyl isothiocyanate, phosphine, ethylene oxide, carbonyl sulfide and propylene oxide, and a fumigation method for killing wood parasitic nematodes by using said fumigant. | 2009-01-15 |
20090018216 | POLYMER MICELLE COMPLEX INCLUDING NUCLEIC ACID - It is an object of the present invention to provide: a polyion complex that sufficiently retains a photosensitizing substance in serum and is excellent in terms of structural stability; a nucleic acid polyplex as a constituent thereof; and a device and a kit for delivering a nucleic acid into a cell. | 2009-01-15 |
20090018217 | VOLATILE SULFIDE PRODUCTION INHIBITOR AND METHOD FOR INHIBITING THE PRODUCTION OF VOLATILE SULFIDE USING THE INHIBITOR - The object of the present invention is to establish a volatile sulfide production inhibitor that can inhibit the production of volatile sulfides from a composition and to provide a method for inhibiting the production of volatile sulfides from a composition by using the inhibitor. The object are solved by providing a volatile sulfide production inhibitor comprising L-ascorbic acid 2-glucoside as an effective ingredient and a method for inhibiting the production of volatile sulfides from a composition by incorporating the volatile sulfide production inhibitor into the composition. | 2009-01-15 |
20090018218 | METHODS OF MODIFYING AMYLOID beta OLIGOMERS USING NON-PEPTIDIC COMPOUNDS - Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β | 2009-01-15 |
20090018219 | METHOD OF PRODUCING SILICA SOLS WITH CONTROLLABLE BROAD SIZE DISTRIBUTION AND MINIMUM PARTICLE SIZE - Colloidal silica having a controllable broad particle size distribution and a controllable minimum particle size is disclosed and claimed. Particles below a predetermined size are excluded from the product colloidal silica of the invention. A method for continuously producing the desired colloidal composition is disclosed comprising the steps of providing preformed silica particles having a surface area which controls the particle size of the colloidal silica product, adding a feed silica comprising an alkaline solution and silicate at a feed rate which is less than a nucleation rate. | 2009-01-15 |
20090018220 | METHANOL SYNTHESIS - A process for synthesising methanol comprises the steps of: (i) reforming a hydrocarbon feedstock and separating water to generate a make-up gas comprising hydrogen and carbon oxides, the make-up gas mixture having a stoichiometric number, R, R=([H | 2009-01-15 |
20090018221 | METHODS AND APPARATUS FOR PRODUCING SYNGAS AND ALCOHOLS - This invention features methods and apparatus for producing syngas from any carbon-containing feed material. In some embodiments, a substoichiometric amount of oxygen is used to enhance the formation of syngas. In various embodiments, both oxygen and steam are added during the conversion of the feed material into syngas. The syngas can be converted to alcohols, such as ethanol, or to other products. | 2009-01-15 |
20090018222 | METHODS AND APPARATUS FOR PRODUCING SYNGAS - This invention features methods and apparatus for producing syngas from any carbon-containing feed material. In some embodiments, a substoichiometric amount of oxygen is used to enhance the formation of syngas. In various embodiments, both oxygen and steam are added during the conversion of the feed material into syngas. The syngas can be converted to alcohols, such as ethanol, or to other products. | 2009-01-15 |
20090018223 | Recycle of electrical equipment - The conventional techniques for recycling an electrical equipment including a hardened epoxy resin and electroconductive material has involved conventional problems that a catalyst is degraded to an extent that it can be no longer reused when a water is contained in a dissolving system. | 2009-01-15 |
20090018224 | PROCESS FOR THE DRYING OF FOAMS COMPOSED OF AQUEOUS PU DISPERSIONS - The invention relates to the drying of foams by means of microwave radiation, and in particular, where the foams are obtained from aqueous polyurethane dispersions (PU dispersions). | 2009-01-15 |
20090018225 | High processing tepmerature foaming polymer composition - A foaming composition includes a polymer having a melting temperature above 250° C., and an organic salt as chemical foaming agent having a decomposition temperature above the melting point of the polymer, where the organic salt is selected from the group of citrate derivatives and tartrate derivatives, or a mixture thereof. | 2009-01-15 |
20090018226 | Polyurethane foam containing synergistic surfactant combinations and process for making same - The present invention relates to a composition and process for preparing fine-celled polyurethane foam obtained from frothing a polyurethane foam-forming composition possessing a synergistic combination of silicone surfactants. | 2009-01-15 |
20090018227 | Fine Particle-Dispersed Polyol Composition, Method for Producing Polymer Polyol, and Method for Producing Polyurethane Resin - A polyol composition comprising a polyol (a) and resin fine particles (b) dispersed in the polyol (a), and a method for producing the polyol composition are provided, wherein the resin fine particles (b) are particles such that an arithmetic standard deviation by volume of a particle size distribution of the particles, derived from respective values in 85 divisions of a range of 0.020 to 2000 μm determined by a laser diffraction/scattering particle size distribution analyzer, is not more than 0.6. A resin fine particle-dispersed polyol composition that, even if the resin particles dispersed in the polyol have a small particle diameter, allows the production of a polyurethane resin having an excellent mechanical strength such as elongation at break, and a method for producing the same, are provided. | 2009-01-15 |
20090018228 | PROCESSES FOR PRODUCING POLYURETHANE FOAMS CONTAINING ALKOXYSILANE FUNCTIONAL POLYMERS AND USES THEREFOR - Processes comprising: (a) providing a composition comprising at least one silane-terminated polyurethane preploymer prepared by a process comprising: reacting (A) at least one polyether having a number average molecular weight (Mn) of 2000 to 8000 g/mol, and comprising 10 to 30 wt % ethylene oxide units based on all alkylene oxide units in the polyether; with (B) at least one isocyanate and alkoxysilane group-containing compound of the formula (I): | 2009-01-15 |
20090018229 | Nanocomposites prepared using nanoadditive containing dispersed silicate layers or inorganic nanoparticles - Nanocomposites of silicate layers or inorganic nanoparticles dispersed in a polymer or copolymer matrix are prepared by solution blending or melt blending the polymer or copolymer with nanoadditive containing from 20 to 50 weight percent silicate layers or inorganic nanoparticles dispersed in a different polymer or copolymer of M | 2009-01-15 |
20090018230 | Yellow radiation curing inks - A radiation curing ink comprising from 60 to 90% of an acrylic binder, optionally reactive diluents and/or non-reactive resins, from 1 to 20% of a photoinitiator and optionally a sensitizer, from 5 to 25% of a pigment of the formula | 2009-01-15 |
20090018231 | RADIATION-CURABLE COATINGS FEATURING IMPROVED ADHESION - Mixtures comprising at least one radiation-curable composition (I) and at least one pressure-sensitive adhesive (II). | 2009-01-15 |
20090018232 | METHOD FOR THE FORMATION OF HYDROGEL MULTILAYERS THROUGH SURFACE INITIATED PHOTOPOLYMERIZATION - Multiple-layer hydrogels and methods of forming hydrogels having multiple layers are disclosed. The hydrogels are formed of prepolymerization solutions comprising monomers or macromers, particularly polyethylene glycol. The layers are covalently bonded, and the hydrogels may comprise two or more layers. | 2009-01-15 |
20090018233 | Crosslink Agents and Dual Radical Cure Polymer - A synthetic route to polymers comprised of at least two monomers each with a very different reactivity ratio by using a corresponding crosslink agent for each monomer. Novel crosslink agents are described that provide for the copolymerization of at least one hydrophilic monomer with at least one lens monomer typically used to prepare materials for ophthalmic lenses. The new crosslink agents have a relatively high selectivity for the hydrophilic monomer and limited reactivity with the crosslink agent used to polymerize the lens monomer. | 2009-01-15 |
20090018234 | DENTAL CEMENT - In order to decrease hydroscopic expansion of a resin-modified dental glass ionomer cement without losing high mechanical strength and adhesiveness to tooth structure and to lower a solubility, a dental cement consists of a liquid agent which includes a (meth)acrylate monomer having an acid group; a (meth)acrylate monomer having two or less hydroxyl groups and/or amino groups, not having an acid group, and having 160 or more molecular weight; water if necessary; and an amine compound as a polymerization initiator for a polymerization catalyst in a powder agent, and a powder agent which includes metal oxide powder used for fluoroaluminosilicate glass powder, dental zinc phosphate cement powder or dental carboxylate cement powder; and an organic aromatic compound and a peroxide, where the organic aromatic compound contains at least one —SO | 2009-01-15 |
20090018235 | ENVIRONMENTALLY DEGRADABLE POLYMERIC COMPOSITION AND PROCESS FOR OBTAINING AN ENVIRONMENTALLY DEGRADABLE POLYMERIC COMPOSITION - The present invention refers to a polymeric composition prepared from a biodegradable polymer defined by poly-hydroxybutyrate (PHB) or copolymers thereof, and at least one other biodegradable polymer, such as polycaprolactone (PCL) and poly (lactic acid) (PLA), so as to alter its structure, and further at least one additive of the type of natural filler and natural fibers, and, optionally, nucleant, thermal stabilizer, processing aid, with the object of preparing an environmentally degradable material. According to the production process described herein, the composition resulting from the mixture of the modified biodegradable polymer and additives can be utilized in the manufacture of injected packages for food products, injected packages for cosmetics, tubes, technical pieces and several injected products. | 2009-01-15 |
20090018236 | ANTIHAZING AGENT FOR NONCRYSTALLINE CYCLOOLEFIN RESINS, RESIN COMPOSITIONS, AND OPTICAL ELEMENTS - An antihazing agent for noncrystalline cycloolefin resins which can inhibit the hazing of the resins due to fine cracking caused by environmental change, particularly, environmental change from high temperature and humidity atmosphere to ordinary temperature and humidity atmosphere without losing the characteristics inherent in the resins to keep the transparency of the resins and inhibit the light transmittance thereof from lowering; noncrystalline cycloolefin resin compositions containing the agent; and optical elements made from the compositions. A compound component containing a metal rosinate as the main component is used as the antihazing agent for noncrystalline cycloolefin resins. It is particularly preferable that the antihazing agent further contain one or more members selected from the group consisting of alkali metal salts, alkaline earth metal salts, and Group 12 metal salts. | 2009-01-15 |
20090018237 | POLYLACTIC ACID-CONTAINING RESIN COMPOSITION AND PRODUCT MOLDED THEREFROM - A polylactic acid-containing resin composition is provided which comprises 100 parts by mass of a resin containing 20 to 98 mass % of polymethyl methacrylate and 80 to 2 mass % of polylactic acid, and 1 to 100 parts by mass of an impact resistance improving material. The impact resistance improving material is a polymeric material comprising an acrylic monomer unit. The impact resistance improving material has a refractive index of 1.402 to 1.542. The resin composition is excellent in heat resistance, moldability, durability, transparency and impact resistance. | 2009-01-15 |
20090018238 | METHOD FOR PRODUCING RUBBER-FILLER MASTER BATCH - A method for producing a rubber-filler master batch which comprises mixing a rubber solution obtained by dissolving a diene-based rubber in an organic solvent into a slurry obtained by dispersing in water, in advance, carbon black, silica and/or at least one inorganic filler represented by the following general formula (I): | 2009-01-15 |
20090018239 | UNDERFILL ADHESIVES - In accordance with the present invention, it has now been found that glycidyl epoxy resins containing substitution on the epoxide ring can be used with conventional epoxy curing agents and fluxing agents to produce underfill adhesives that are suitable for use with silver-based alloys. Owing to the structural similarity of the new materials to conventional epoxy resins, physical and material properties of the invention formulations are altered little, if at all, relative to products currently in use, and so are highly compatible with existing processes. | 2009-01-15 |
20090018240 | Use of Water-Soluble or Water-Dispersible Polymers as Additives in
Mineral Building Materials - The present invention relates to the use of water-soluble or water-dispersible polymers as additives in mineral building materials. The novel polymers are obtainable by polymerizing alkoxylated derivatives of 3-allyloxy-1,2-propanediol with ethylenically unsaturated mono- or dicarboxylic acids or the anhydrides, esters or mixtures thereof and, if appropriate, with one or more further ethylenically unsaturated monomers C. | 2009-01-15 |
20090018241 | HALOGEN-FREE PHOSPHOROUS EPOXY RESIN COMPOSITION - The present invention relates to a halogen-free phosphorous epoxy resin composition, primarily used as an adhesive for the printed circuit board. The composition comprises a halogen-free phosphorous contained epoxy resin which reduces the addition amount of additional flame retardant; in order to offer flame retardancy while maintaining high flexibility of flexible printed circuit board. | 2009-01-15 |
20090018242 | POLYETHERIMIDE/POLYPHENYLENE ETHER SULFONE BLENDS - Compositions comprise phase separated polyetherimide/polyphenylene ether sulfone blends. The dispersed phase has an average cross sectional size of 0.1 to 10 micrometers. The composition retains has good hydrolytic stability and is capable of withstanding steam autoclaving at temperatures of 130 to 138° C. | 2009-01-15 |